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Abstract
The PI3K (phosphatidylinositol-3-kinase)/mTOR (mammalian target of rapamycin) pathway is frequently activated in
endometrial cancer through various PI3K/AKT-activating genetic alterations. We examined the antitumor effect of NVP-
BEZ235—a dual PI3K/mTOR inhibitor—and RAD001—an mTOR inhibitor—in 13 endometrial cancer cell lines, all of which
possess one or more alterations in PTEN, PIK3CA, and K-Ras. We also combined these compounds with a MAPK pathway
inhibitor (PD98059 or UO126) in cell lines with K-Ras alterations (mutations or amplification). PTEN mutant cell lines without
K-Ras alterations (n=9) were more sensitive to both RAD001 and NVP-BEZ235 than were cell lines with K-Ras alterations
(n=4). Dose-dependent growth suppression was more drastically induced by NVP-BEZ235 than by RAD001 in the sensitive
cell lines. G1 arrest was induced by NVP-BEZ235 in a dose-dependent manner. We observed in vivo antitumor activity of
both RAD001 and NVP-BEZ235 in nude mice. The presence of a MEK inhibitor, PD98059 or UO126, sensitized the K-Ras
mutant cells to NVP-BEZ235. Robust growth suppression by NVP-BEZ235 suggests that a dual PI3K/mTOR inhibitor is a
promising therapeutic for endometrial carcinomas. Our data suggest that mutational statuses of PTEN and K-Ras might be
useful predictors of sensitivity to NVP-BEZ235 in certain endometrial carcinomas.
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Introduction
Constitutive activation of the PI3K (phosphatidylinositol 3-
kinase) pathway results from various types of alterations, including
changes to RTKs (receptor tyrosine kinases), Ras, PIK3CA (the
p110alpha catalytic subunit of PI3K), and PTEN [1]. Endometrial
cancer is the fourth most frequent cancer in women [2]. There are
two pathogenetic types of endometrial carcinomas: estrogen-
dependent type I (endometrioid adenocarcinomas) and estrogen-
independent type II (high-grade carcinomas). Approximately 80%
of endometrial carcinomas are classified as type I [3,4]. Mutations
of K-Ras (10–20%), PTEN (34–56%), and PIK3CA (25–36%) are
frequently observed in endometrial cancer [5–8]. In addition, we
previously revealed that chromosomal imbalances in the Ras-
PI3K pathway genes (NF1, PTEN, K-Ras, and PIK3CA) are also
common in endometrial cancer [9], indicating that the Ras-PI3K
pathway is activated in the majority of endometrial cancers.
Novel therapeutics targeting the PI3K/mTOR (mTORC1/2)
pathway are being intensively developed. The first clinically
approved inhibitors are rapamycin analogs (rapalogs), such as
everolimus (RAD001) and temsirolimus, targeting the mTORC1
complex for use with advanced renal cell carcinomas [10–13].
However, clinical trials with single-agent rapalog therapies have
shown limited response rates in other cancer types [14]. Several
potent and selective PI3K inhibitors have recently entered early-
phase clinical trials for treatment of various malignant tumors
[15]. The limitation of the rapalogs might be explained by the
activity of the mTORC1-independent substrates of Akt, including
GSK3beta and FOXO1/3a. Rapalogs do not prevent mTORC2-
dependent phosphorylation of Akt on Ser-473 or PDK1-depen-
dent phosphorylation of Akt on Thr-308 [16,17]. In addition,
rapalogs may cause feedback activation of the PI3K-Akt pathway
mediated by insulin-like growth factor-1 receptor (IGF-1R)
signaling [18]. Therefore, a dual PI3K/mTOR inhibition might
be a more rational therapeutic option than mTOR inhibition
alone in tumors with PI3K-activating mutations.
Developing predictive biomarkers of the PI3K/mTOR inhib-
itors is important; however, the existence of alterations in the PI3K
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necessarily a good biomarker for these compounds. Indeed,
tumors with alterations in Ras and RTK do not respond
sufficiently to simple PI3K pathway inhibition [19–22]. Moreover,
multiple genetic alterations in the RTK-Ras-PI3K pathway are
reported in many cancers [1]. It remains to be determined which
types of alterations are useful as predictive biomarkers.
In this study, we firstly evaluated the antitumor effect of a dual
PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor,
RAD001 (everolimus), in a panel of endometrial cancer cell lines.
Second, we analyzed the antitumor effect of NVP-BEZ235 and
RAD001 in vivo. Third, we focused on the predictive biomarkers
to the PI3K/mTOR inhibitors, using the mutational status of K-
Ras, PTEN, and PIK3CA. Finally, we addressed the antitumor
effect of the combined inhibition of the PI3K/mTOR and MAPK
pathways in cells with K-Ras alterations.
Materials and Methods
Cell lines and reagents
Culture conditions of 13 endometrial cancer cell lines (en-
dometrioid adenocarcinomas) were described previously [8].
NVP-BEZ235 and RAD001 (everolimus) were kindly provided
by Novartis Pharma AG (Basel, Switzerland). MAPK pathway
(MEK) inhibitors PD98059 and UO126 were purchased from Cell
Signaling Technology (Beverly, MA).
PCR and sequencing
The mutational status of 13 cell lines was analyzed by PCR and
direct sequencing. The PCR conditions and primers for PTEN
(exons 1–9), K-Ras (exon 1 and 2), and AKT1 (exon 4) were
described previously [8,23,24]. The mutational status of PIK3CA
was analyzed by RT-PCR with LA-Taq according to the
manufacturer’s protocol (Takara BIO, Madison, WI) to cover
entire coding region. The PCR primers were the following:
forward, 59-CCCGAGCGTTTCTGCTTTGGGACAACC-39;
reverse, 59-AGCGTTTCTGCTTTGGGACAACCATACATC-
39.
Immunoblotting
Cells were treated with each drug for the indicated time and
concentrations and then lysed as described previously [7].
Antibodies to total Akt, phospho-Akt (Ser473), phospho-Akt
(Thr308), phospho-GSK3beta (Ser9), total S6, phospho-S6
(Ser235/236, Ser 240/244), p-4EBP1 (Thr37/46), total FoxO1,
phospho-FoxO1 (Thr24), phospho-FoxO3a (Thr32), phospho-
ERK (ERK1/2-Thr202/Tyr204), total ERK (Cell Signaling
Technology, Beverly, MA), and beta-actin (Sigma-Aldrich, St.
Louis, MO) were used for immunoblotting, as recommended by
the manufacturer, and were detected by an ECL western blot
detection kit (Amersham Biosciences, Piscataway, NJ) or Immo-
bilon western detection reagents (Millipore Biosciences, Temecula,
CA).
Proliferation assays
Cell viability assays were performed with the Cell Counting Kit-
8 (cell viability colorimetric assay), using the tetrazolium salt WST-
8 (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfo-
phenyl)-2H-tetrazolium, monosodium salt) (Dojindo, Tokyo,
Japan), as an MTT (Methyl thiazolyl tetrazorium) assay. In 96-
well plates, 1610
5 cells were seeded with 10% fetal bovine serum
(FBS) and treated with increasing doses of NVP-BEZ235 or
RAD001 for 72 h, starting 24 h after seeding. The WST-8
colorimetric assay was quantified at 415 nm and normalized to the
value of cells treated with DMSO alone. All experiments were
repeated twice.
Cell cycle analysis
Cells (5610
5) were seeded in 60-mm dishes (with 10% FBS) and
treated with reagents (such as NVP-BEZ235, RAD001, PD98059,
or UO126) for 48 h. Floating and adherent cells were collected by
trypsinization and washed twice with PBS. Cells were resuspended
in buffer containing ethanol and PBS at a ratio of 7:3 at 220uC
overnight. After being washed twice with PBS, cells were
incubated in ribonuclease solution (0.25 mg/mL) (Sigma) for
30 min at 37uC, followed by staining with propidium iodide
(50 mg/mL) (Dojindo, Japan) on ice for 30 min in the dark. Cells
were then incubated in 70% ethanol at 220uC overnight, treated
with 20 mg/mL RNase A, stained with 0.5 mg/mL propidium
iodide, and evaluated by flow cytometry (BD FACS Calibur HG,
Franklin Lakes, NJ). Cell cycle distribution was analyzed with
CELL Quest pro ver. 3.1. (Beckman Coulter Epics XL, Brea, CA).
The experiments were repeated 3 times.
Ethics statement for animal experiments and clinical data
Ethics statement for animal experiments: This study was
approved by Animal Care and Use Committee, The University
of Tokyo. The approval number is Med-P09-051. Athymic
BALB/c mice (CLEA JAPAN, Tokyo, Japan) were maintained
in an SPF (Specific Pathogen Free) facility according to our
institutional guidelines, and experiments were conducted under an
approved animal protocol.
This manuscript includes clinical data, which were previously
published elsewhere [7–9,25]. The authors declare that all these
participants provided written informed consent, and the study
design was approved by the Institutional Review Board of the
University of Tokyo Hospital. The approval number is 683.
Tumor xenografts in nude mice
Subcutaneous xenograft tumors in BALB/c mice were estab-
lished by the injection of a 500-mL cell suspension of 10610
6
AN3CA and HEC-59 endometrial carcinoma cells in PBS.
Tumors were removed after exponential growth, cut into 3-mm
pieces, and transplanted subcutaneously into other mice. One
week after tumor transplantation, mice were assigned randomly to
one of three treatment regimens: (1) vehicle (control), (2) NVP-
BEZ235, and (3) RAD001. Each treatment group consisted of 6
mice. NVP-BEZ235 and RAD001 were injected orally (p.o.) at
daily doses of 40 mg/kg and 2.5 mg/kg, respectively. Tumor
volumes (in mm
3) were calculated by the formula: ([major
axis]*[minor axis]2/2). After the treatment, the tumors were
removed and analyzed by Western blot analysis. Tumor weight
(wet weight) was measured, and the average weight was calculated
for each group.
Single nucleotide polymorphism typing array and array
comparative genomic hybridization
A single nucleotide polymorphism (SNP) array was performed
in the HEC-6, 50B, 59, 88, 108, 116, 151, and HHUA cell lines.
Experimental procedures for GeneChip were performed accord-
ing to the GeneChip Expression Analysis Technical Manual
(Affymetrix, Santa Clara, CA, USA) with the use of a human
mapping 250K Nsp array [9]. Array comparative genomic
hybridization (CGH) was performed using arrays of 2464 BAC
clones (HumArray2.0) in the remaining 5 cell lines (AN3CA,
HEC-1B, Ishikawa, KLE, and RL95-2) as described previously
[7].
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Statistical comparisons of mean final tumor volumes in the
xenograft studies were made using a one-way analysis of variance
(ANOVA). P,0.05 was considered statistically significant.
Results
Classification of endometrial cancer cells according to
the mutational status of PIK3CA, PTEN, and K-Ras
We previously reported copy number losses for PTEN (26%)
and gains for PIK3CA (19%) and K-Ras (13%) in our 31 clinical
samples, in addition to mutations of K-Ras, PTEN, PIK3CA, and
AKT1 [8,9,25]. We confirmed that all 13 endometrial cancer cell
lines possess one or more alterations (mutations and/or copy
number alterations) in the PIK3CA, PTEN, and K-Ras genes
(Table 1, Figure 1A and 1B). AKT1 mutations were not detected in
these 13 cell lines. We classified 13 endometrial cancer cell lines
into 4 groups according to the mutational status of PIK3CA, PTEN,
and K-Ras (Table 1): group A (n=4), with coexistent mutations of
PIK3CA and PTEN; group B (n=5), with PTEN mutation alone;
group C (n=2), with coexistent mutations of K-Ras and PIK3CA;
and group D (n=2), with copy number gain of K-Ras (without any
mutations in these 3 genes). We previously reported that PTEN
expression was not detected in PTEN mutant endometrial cancer
cell lines [8]. We have found no endometrial cell lines without any
alterations in the Ras-PI3K pathway, suggesting that this pathway
is essentially activated in the majority of endometrial cancer cell
lines.
Mutations in PIK3CA and/or PTEN, in the absence of
mutations in K-Ras, define the antiproliferative response
to NVP-BEZ235 and RAD001 in endometrial cancer cell
lines
We performed MTT (Methyl thiazolyl tetrazorium) assay by
NVP-BEZ235 and RAD001 in the 13 endometrial cell lines.
RAD001 (100 nM) showed a growth inhibitory effect against 10 of
the 13 cell lines (including all 9 group A and B cell lines), with a
30–70% reduction in cells (Figure 2A–2D). NVP-BEZ235
(100 nM) inhibited cell growth, with a 30–90% reduction in all
13 cell lines. The IC50 values for cell proliferation by RAD001
were greater than 100 nM (non-sensitive) in 6 out of the 9 cell lines
in groups A and B, whereas the IC50 values for NVP-BEZ235
were less than 100 nM (sensitive) in all 9 cell lines in groups A and
B (Table 1). Dose-dependent growth suppression was more clearly
induced by NVP-BEZ235 than by RAD001 in 8 of the 9 cell lines
in groups A and B (Figure 2A–2D). The IC50 values for all 4 cell
lines in groups C and D were greater than 100 nM for NVP-
BEZ235 (Table 1). Taken together, these data show that the
existence of PTEN and/or PIK3CA mutations without K-Ras
mutations is associated with sensitivity to NVP-BEZ235. In
addition, high-dose NVP-BEZ235 might be more broadly effective
than RAD001 for treatment of endometrial carcinomas. Growth
curves of all cell lines in 1 graph were available for both NVP-
BEZ235 and RAD001, respectively (Figures S1 and S2).
NVP-BEZ235 suppresses phosphorylation of Akt,
GSK3beta, S6, and 4EBP1, whereas RAD001 suppresses
phosphorylation of S6 and 4EBP1
We performed immunoblotting with lysates prepared from cells
treated with NVP-BEZ235 or RAD001. The phosphorylation (p-)
levels of 4E-BP1 and S6 were clearly suppressed by both inhibitors
at low concentrations (0.625–2.5 nM). NVP-BEZ235 also sup-
pressed the level of p-Akt (Ser473 and Thr308) (50–1000 nM) in
these cells (Figure 3A and 3B). RAD001 did not suppress the
phosphorylation level of Akt at any dose (Figure 3A and 3B). The
dose dependency of the phosphorylation levels of mTORC1-
dependent proteins (4E-BP1 and S6) and Akt suggests that NVP-
BEZ mainly works as an mTOR (mTORC1) inhibitor at lower
concentrations and functions as a dual PI3K/mTOR inhibitor at
higher concentrations.
Next, we performed time-course experiments with NVP-
BEZ235 and RAD001. Long-term exposure to NVP-BEZ235
(250 nM) resulted in sustained inhibition of p-S6 and p-4E-BP1.
However, the phosphorylation levels of Akt and GSK3beta (an
mTORC1-independent protein) recovered nearly to the baseline
levels within 24 h (Figure 3C). Exposure to RAD001 resulted in a
drastic reduction in the level of p-4EBP1 in 15 min, but the level
Table 1. Classification of endometrial cancer cell lines by mutational status and IC50 values to NVP-BEZ235 and RAD001.
Group Cell line Mutational status Copy number alterations IC50 (nM)
PIK3CA PTEN (mutated exons) K-Ras PIK3CA PTEN K-Ras BEZ235 RAD001
A HEC-116 Mut (R88Q) Mut 6(M), 7(N) wild type nl nl nl 19 6
HEC-6 Mut (R108H) Mut 4(F), 8(F) wild type nl nl nl 19 400
HEC-59 Mut (R38C) Mut 2(M), 7(N), 7(M), 7(F) wild type nl nl nl 24 220
HEC-88 Mut (E365K) Mut 5(M), 6(M), 8(M), 8(M) wild type nl nl nl 44 440
B AN3CA wild type Mut 5(N) wild type nl nl nl 20 14
Ishikawa wild type Mut 8(F), 8(F) wild type Gain nl nl 30 50
HEC-151 wild type Mut 2(M), 4(F) wild type nl nl nl 51 130
HEC-108 wild type Mut 1(F), 8(F) wild type nl nl nl 55 730
RL95 wild type Mut 8(F), 8(F) wild type nl nl nl 90 .1000
C HEC-1B Mut (G1049R) wild type Mut (G12D) Gain nl nl 220 200
HHUA Mut (R88Q) Mut 5(F), 8(F) Mut (G12V) nl nl nl 250 .1000
D KLE wild type wild type wild type nl nl Gain 110 .1000
HEC-50B wild type wild type wild type Gain nl Gain 100 .1000
(M) Missense mutation, (N) Non-sense mutation, (F) Frameshift mutation.
doi:10.1371/journal.pone.0037431.t001
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suppressed over the time course (Figure 3C). We confirmed that
the phosphorylation level of ERK was not affected by both
RAD001 and NVP-BEZ235 (Figure 3A–3C).
NVP-BEZ235 robustly induces dose-dependent G1 arrest
in ‘‘sensitive’’ cells
We conducted fluorescence-activated cell sorting (FACS)-based
cell cycle analyses before and after NVP-BEZ235 or RAD001
treatment in a subset of the cell lines. At a low concentration
(10 nM), G1 arrest was slightly induced by both RAD001 and
NVP-BEZ235 (,15%) in group A and group B cell lines
(Figure 4A–4D). At a higher concentration (100 nM), G1 arrest
was much more effectively induced by NVP-BEZ235 than by
RAD001 in three of the four cell lines (Figure 4A–4D). Dose-
dependent G1 arrest by NVP-BEZ235 was confirmed in all the
other group A and B cell lines (data not shown). G1 arrest was also
observed to be induced by either RAD001 or NVP-BEZ235 in the
4 cell lines of groups C and D; however, the dose-dependent effect
of NVP-BEZ235 was not significant, except for HEC-1B cells
(Figure S3A–S3D). The sub-G1 population was not significantly
induced by either inhibitor in all cell lines examined, suggesting
that the antitumor effect of these inhibitors is predominantly
cytostatic, not cytotoxic.
In vivo antitumor effect of NVP-BEZ235 and RAD001 in a
mouse xenograft model
We examined in vivo antitumor activity of both NVP-BEZ235
and RAD001 in mice inoculated with either group A (HEC-59) or
group B (AN3CA) cells. Both NVP-BEZ235 and RAD001
significantly suppressed the tumor growth of the xenografts,
compared with the control (vehicle). No significant adverse effects,
including a body weight loss of more than 10%, were observed in
the examined mice (data not shown). Inconsistent with the in vitro
data, the effects of NVP-BEZ235 and RAD001 were comparable
(Figure 5A–5C).
We then evaluated the phosphorylation levels of the targeted
molecules as pharmacodynamic markers. We extracted proteins
from the second, third, and fourth largest tumors of each group.
Although there were variations in the phosphorylation levels in the
control group, NVP-BEZ235 suppressed the phosphorylation
levels of Akt, FOXO1/3a, and S6 at 1 h. However, the
phosphorylation levels of these proteins recovered to the baseline
levels within 24 h (Figure 5D). RAD001 had clearly suppressed the
p-S6 level at 1 h, and the effect partly remained at 24 h after the
treatment (Figure 5D). Taken together with the in vitro
experiments, these results indicate that the antitumor activity of
NVP-BEZ235 might not be sufficiently maintained during
treatment.
Figure 1. Copy number gain at the locus of K-Ras (12p12.1) in the two group D cell lines. (A) SNP array ‘karyograms’ (250K) of HEC-50B
cells. The graph shows the total copy number through chromosome 9p-X. The locus of K-Ras is amplified as indicated. (B) Array CGH of KLE cells. The
graphs show total copy number throughout the entire genome (Left) and chromosome 12 (Right). The locus of K-Ras is amplified as indicated.
doi:10.1371/journal.pone.0037431.g001
Dual PI3K/mTOR Inhibitor in Endometrial Cancer
PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e37431Figure 2. Inhibition of cell proliferation by NVP-BEZ235 and RAD001. (A)–(D) WST-8 assay showing the sensitivity of endometrial cancer
cells to NVP-BEZ235 and RAD001 at increasing concentrations of drug (nmol/L) for 72 h. The data was normalized to the value of control cells. (A)
Four group A cell lines with double mutations of PIK3CA and PTEN, (B) Five group B cell lines with PTEN mutations, (C) Two group C cell lines with
coexistent mutations of K-Ras and PIK3CA, and (D) Two group D cell lines with chromosomal copy number amplification at the locus of K-Ras. All
experiments were repeated 3 times, and each value is shown as the mean of 3 experiments 6 S.D.
doi:10.1371/journal.pone.0037431.g002
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additively) suppresses cell proliferation and induces G1
arrest in K-Ras mutant endometrial cell lines
Because the 4 cell lines with K-Ras alterations (HEC-1B,
HHUA, KLE, and HEC-50B) were less sensitive to both NVP-
BEZ235 and RAD001, compared with K-Ras wild-type cells with
PTEN mutations (groups A and B), we combined NVP-BEZ235
(or RAD001) with a MEK inhibitor (PD98059 or UO126) for use
in these 4 cell lines (groups C and D). MTT assay revealed that
PD98059 (50 mM) or UO126 (10 mM) alone showed a limited
growth inhibitory effect with a 10–30% reduction in the 4 cell lines
(Figure 6A and 6B, Figure S4A and S4B). However, after
treatment with NVP-BEZ235 (250 nM) combined with
PD98059 (20–50 mM) or UO126 (10 mM), cell proliferation was
suppressed synergistically or additively with a 45–70% reduction
(Figure 6A and 6B, Figure S4A and S4B). FACS analysis showed
that G1 arrest was markedly induced by a combination of
PD98059 (or UO126) and NVP-BEZ235 (Figure 6C and 6D,
Figure S4C and S4D). In HEC-1B and HEC-50B cells, the G0/
G1 ratio was significantly higher for the combination of PD98059
and NVP-BEZ235 than for either compound alone (Figure 6C
and 6D). A similar synergistic effect was also observed with the
combination of PD98059 (or UO126) and RAD001 (250 nM),
although the effect of RAD001 was weaker than that of NVP-
BEZ235 (Figure 6C and 6D, Figure S4C and S4D). The sub-G1
population was not significantly increased in groups C and D cells
when using the combination of NVP-BEZ235 and a MEK
inhibitor, PD98059 (,5%), as compared to that when using the
control or NVP-BEZ235 alone.
Phosphorylation levels of Akt, S6, and ERK in cells with K-
Ras alterations treated with RAD001, NVP-BEZ235, and
PD98059
We analyzed the PI3K/mTOR and MAPK signaling pathways
in cells of groups C and D by western blotting. NVP-BEZ235 at
250 nM suppressed the phosphorylation levels of AKT and S6 in
HEC-1B, HEC-50B, and KLE cells. In HHUA cells, the total
AKT level was slightly elevated, although the p-AKT level was not
significantly changed by NVP-BEZ235 alone (Figure 7). RAD001
at 250 nM suppressed the p-S6 level in all cells of groups C and D
(Figure 7). Both RAD001 and NVP-BEZ235 did not suppress the
p-ERK level, whereas a MEK inhibitor, PD98059, decreased the
p-ERK level in these cells.
Figure 3. Inhibition of PI3K/mTOR signaling by NVP-BEZ235 and inhibition of mTOR signaling by RAD001 in endometrial cancer
cell lines. (A)–(B) Western blot of total lysates of HEC-88 (group A) and HEC-108 (group B) cells, treated with NVP-BEZ235 or RAD001 at
concentrations ranging from 0 to 1,000 nmol/L with 10% fetal bovine serum (FBS). phospho-Akt (Ser473, Thr308), phospho-S6 (Ser235/236, Ser240/
244), and phospho-4EBP1 (Thr 37/46) levels are shown with total Akt level for a loading control. (C) Western blot of total lysates of HEC-6 (group A)
cells treated with NVP-BEZ235 or RAD001 at a dose of 100 nM for up to 48 hours with 10% FBS. Phosphorylation levels of the PI3K/mTOR signaling
are shown with loading controls.
doi:10.1371/journal.pone.0037431.g003
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We examined activity of the PI3K/mTOR pathway inhibitors
in endometrial cancer cell lines with a particular focus on (i) the
antitumor effect of an mTOR inhibitor (RAD001) and a dual
PI3K/mTOR inhibitor (NVP-BEZ235), (ii) predictive biomarkers
of the mutational status of the PI3K pathway genes, and (iii)
combined inhibition of the MAPK pathway and the PI3K/
mTOR pathway in K-Ras mutant cells. MTT assay and FACS
analysis in a panel of endometrial cancer cell lines revealed a clear
dose-dependent effect of NVP-BEZ235 on cell proliferation. NVP-
BEZ235 induces G1 arrest much more efficiently at a higher
concentration (100 nM) than at a lower concentration (10 nM). In
contrast, RAD001 does not show evidence of such dose
dependency. Previous reports also suggested that NVP-BEZ235
was more effective than rapalogs at higher concentrations [26,27].
PI3K activity might not be sufficiently suppressed by 100 nM
NVP-BEZ235, as indicated by the observation that decreased
phosphorylation of Akt (Thr308) is not observed at 50 nM but is
observed at 250 nM or higher. In addition, IC50 values were
under 100 nM in cells from groups A and B. These data are in
agreement with previous reports on other cancers that indicate a
discrepancy between the basal activity of the PI3K/Akt pathway
and the biochemical activity of NVP-BEZ235 [26–29]. Neverthe-
less, the dose-dependent antiproliferative activity at concentrations
$250 nM suggests that the effect of NVP-BEZ235 was, at least in
part, caused by inhibition of the PI3K/Akt pathway. Our data
suggest that a dual inhibitor of PI3K/mTOR might be a more
promising therapeutic strategy than a single mTOR inhibitor in
endometrial cancer.
Our in vivo studies in 2 cell lines of xenograft mice support the
in vitro findings that inhibition of the PI3K/mTOR axis has an
antitumor effect in endometrial cancers. We did not see any
superior efficacy of NVP-BEZ235 in the in vivo study. The
concentrations we used were 40 mg/kg for NVP-BEZ235 and
5 mg/kg for RAD001, which are equivalent with the previous in-
vivo experiments [26,28,30–32]. In a pharmacodynamic analysis,
the levels of p-Akt, p-GSK3beta, p-FOXO1/3a, and p-S6 in
tumors returned to the baseline levels within 24 h after admin-
istration of NVP-BEZ235, suggesting that inhibition of PI3K
signaling by NVP-BEZ235 might not be sufficiently maintained
over time. This is compatible with previous data showing that
inhibition of p-Akt (Ser473) was maintained for 16 h, with
recovery to baseline levels at 24 h [33]. It remains to be
determined which oral dosing schedule is optimal in treatment
of endometrial cancer. As well, the mechanisms of in-vivo anti-
tumor effect by these drugs should be more clarified, as inhibition
of mTOR might result in anti-angiogenic effect by suppressing
HIF1-VEGF pathway [34].
Figure 4. Flowcytometric analysis of cell cycle in cancer cells treated with either NVP-BEZ235 or RAD001. (A–D) Cells (5610
5) were
seeded in the presence of 10% serum and treated with NVP-BEZ235 or RAD001 for 48 h at a dose of 10 nM or 100 nM, respectively. A higher dose of
NVP-BEZ235 (100 nM) significantly augmented the percentage of cells in the G0-G1phase of the cell cycle, compared with that of RAD001 (100 nM).
(A)–(B); The data from two group A cells. (C)–(D); the data from two group B cells.
doi:10.1371/journal.pone.0037431.g004
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PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e37431Figure 5. in vivo anti-tumor effect of NVP-BEZ235 and RAD001 in nude mice. Subcutaneous xenograft tumors in athymic BALB/c mice were
established in the injection of endometrial carcinoma cells. Mice were treated with a daily dose of 40 mg/kg (NVP-BEZ235) or with a daily dose of
2.5 mg/kg RAD001 or vehicle alone (control). Each treatment group contained 6 mice; (A) HEC-59 and (B) AN3CA. Tumor volumes were calculated by
the formula {(major axis)*(minor axis)2/2}mm3 twice a week. Groups were compared at the end of treatment. Points, mean; bars, SD, *;p,0.05. (C)
Appearance of subcutaneous tumors in HEC-59 xenografts. (D) Western blot of total lysates from the HEC-59 xenografts. p-Akt, p-FOXO1/3a, p-
GSK3beta, p-S6 were assessed 1 and 24 h after the last drug administration. Total Akt and beta-actin were shown as loading controls.
doi:10.1371/journal.pone.0037431.g005
Dual PI3K/mTOR Inhibitor in Endometrial Cancer
PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e37431Developing predictive biomarkers in therapeutics targeting the
PI3K/mTOR pathway is crucial, as alterations in several
molecules are involved in the activation of this pathway. PIK3CA
mutation and HER2 amplification have been recommended as
useful biomarkers in breast cancer [26,35,36]. Mutant oncogenic
Ras has been suggested as a dominant determinant of resistance in
several solid tumor cells [19,37]. PTEN deficiency is controversial
as a predictive biomarker [26,36,38]. The mechanism of resistance
in PTEN-deficient tumors might be explained by the predominant
activation of p110beta in PTEN mutant tumors [39,40], as NVP-
BEZ235 and most of the other PI3K inhibitors suppress p110beta
less preferentially than the other p110 isoforms. However,
p110beta is not a predominant isoform in endometrial carcinomas
with PTEN mutations [8]. The significance of p110alpha in PTEN
mutant endometrial cancer would be helpful to identify patients
susceptible to NVP-BEZ235. Thus, the existence of PTEN
mutations might be a predictive biomarker for the PI3K/mTOR
inhibitors in endometrial carcinomas. Further in vivo analysis,
including the anti-tumor effect of NVP-BEA235, RAD001, or a
combination of these compounds with a MEK inhibitor on groups
C and D tumors would be necessary to evaluate the utility of these
factors as biomarkers.
Feasibility of mutational analysis of the predictor genes should
be also considered in clinical trials. K-Ras mutational analysis
would be reasonably achievable, as ‘‘hot spot’’ mutations are
located only in 2 exons (codons 12, 13, and 61). However,
mutations of PIK3CA and PTEN are widespread in the entire
coding region. Others and we have reported that PTEN
expression is sufficiently evaluated by immunohistochemistry and
is correlated with mutational status [25,41]. A combination of
screening K-Ras mutations and immunohistochemistry analysis of
PTEN might be a useful and feasible strategy in clinical trials of
endometrial cancer. We previously reported that PIK3CA muta-
tions frequently coexist with K-Ras muations in endometrial cancer
[8]. The two group C cells (HEC-1B and HHUA) with double
mutations of PIK3CA and K-Ras were less sensitive to NVP-
BEZ235, compared with group A/B cells. Thus, PIK3CA mutation
alone might not be a good biomarker in endometrial cancer. Over
5 clinical studies of the rapalogs have been developed in advanced
endometrial cancer. Of them, Oza et al reported phase II study of
Figure 6. Inhibition of cell proliferation and augmentation of G1 arrest by combination of a MEK inhibitor and NVP-BEZ235 (or
RAD001) in cells with alterations in K-Ras (mutation or amplification). (A)–(B) WST-8 assay was performed in HEC-1B (group C) and HEC-50B
(group D) cell lines. All the experiments were repeated three times and each value is shown as the mean of three experiments +/2 S.D. The
combination of a MEK inhibitor (PD98059 or UO126) and NVP-BEZ235 (or RAD001) significantly augmented anti-proliferative effect in these cell lines,
compared with either inhibition alone (p,0.05 by Student’s t-test). (C)–(D) Flowcytometric analysis of cell cycle in HEC-1B and HEC-50B cells. All
experiments were repeated 3 times, and each value is shown as the mean of 3 experiments 6 S.D. Combination of a MEK inhibitor (PD98059 or
UO126) and NVP-BEZ235 significantly augmented the percentage of cells in the G0-G1phase of the cell cycle in these cells. *: p,0.05 by Student’s t-
test.
doi:10.1371/journal.pone.0037431.g006
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PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e37431temsirolimus in endometrial cancer, showing clinical benefit rate
(partial response and stable disease) of 52% in chemoetherapy-
treated patients [42]. They suggested that PTEN loss (immuno-
histochemistry and mutational analysis) and molecular markers of
PI3K/Akt/mTOR pathway did not correlate with the clinical
outcome. It would be clarified whether information of K-Ras
alterations might be helpful in the clinical settings. As well, further
exploration of the other PI3K-activating alterations (such as
mutations of FGFR2 and PIK3R1) and other measurable charac-
teristics (such as standardized uptake value by PET imaging)
would be also necessary to establish the most useful clinical
biomarkers.
She et al reported that various cell lines with double mutations
of K-Ras/BRAF and PIK3CA were resistant to AKT inhibitors, and
suggested that a MEK inhibitor sensitizes these double mutant
cells to AKT or PI3K inhibitors [43]. Our data in the two group C
cells support that a combination of a MEK inhibitor and a PI3K
(AKT) inhibitor might be effective to various types of cancers with
double mutations of K-Ras and PIK3CA. In addition to mutations,
copy number gain of oncogenes is also important for ‘‘oncogene
addiction’’. We previously reported that extensive chromosomal
instability (with 5 or more copy number alterations) is a poor
independent prognostic factor in endometrial carcinomas [10].
Although extensive chromosomal instability is more common in
type II endometrial carcinomas [44], the percentage of extensive
chromosomal instability was 31% in our clinical endometrioid
adenocarcinoma samples [10]. We found that both group D cell
lines (KLE and HEC-50B) harbor extensive CNAs (copy number
alterations), with copy number gain at the locus of K-Ras, although
they do not possess any mutations in K-Ras, PTEN and PIK3CA.
The antiproliferative effect of combined inhibition of MAPK
pathway and PI3K/mTOR pathway in group D cells suggests that
this combination therapy might be an option to treat tumors with
CNA in K-Ras. The dual inhibition of the PI3K and MAPK
pathways might overcome the resistance to PI3K/mTOR
inhibition alone in certain endometrial tumors with K-Ras
alterations through its enhanced cytostatic effect (at least in part).
Cheung et al reported that endometrial cell lines with wild-type
PI3K pathway members were resistant to an mTOR inhibitor,
rapamycin, suggesting that other unexamined factors, including
CNA in K-Ras, might be involved in the anti-tumor effect of
rapalogs [45]. Phosphorylation of 4E-BP1 is not only regulated by
mTORC1, but also by ERK signaling [43,46], suggesting the
crosstalk between PI3K/mTOR pathway and MAPK pathway. It
would be necessary to evaluate the in vivo effect of the combined
therapy in tumors with K-Ras alterations to address the activity of
the MAPK pathway in endometrial cancer.
Supporting Information
Figure S1 Inhibition of cell proliferation by NVP-
BEZ235 in 13 endometrial cancer cells. The growth curves
of all the 13 cells in response to NVP-BEZ235 in the WST-8 assay
(in Figure 2) are shown in one graph.
(PPT)
Figure S2 Inhibition of cell proliferation by RAD001 in
13 endometrial cancer cells. The growth curves of all the 13
cells in response to RAD001 in the WST-8 assay (in Figure 2) are
shown in one graph.
(PPT)
Figure S3 Flowcytometric analysis of cell cycle in
cancer cells treated with either NVP-BEZ235 or
RAD001. (A–D) Cells (5610
5) were seeded and treated with
NVP-BEZ235 or RAD001 for 48 h at a dose of 10 nM or
100 nM, respectively, as described in Figure 4. (A)–(B); The data
from the two group C cells (HEC-1B and HHUA). (C)–(D); the
data from the two group D cells (KLE and HEC-50B).
(PPT)
Figure S4 Inhibition of cell proliferation and augmen-
tation of G1 arrest by combination of a MEK inhibitor
and NVP-BEZ235 (or RAD001) in cells with alterations in
K-Ras (mutation or amplification). (A)–(B) WST-8 assay was
performed in HHUA (group C) and KLE (group D) cell lines. (C)–
(D) Flowcytometric analysis of cell cycle in HHUA (group C) and
Figure 7. Inhibition of PI3K and MAPK signaling pathway by NVP-BEZ235, RAD001, and a MEK inhibitor (PD98059) in endometrial
cancer cell lines with K-Ras alterations. Western blot analysis of total lysates of HEC-1B and HHUA (group C) and HEC-50B and KLE (group D)
cells treated with 1 of the PI3K (or MAPK) signal inhibitors or their combination with 10% FBS. Phospho-Akt, phospho-S6, and phospho-ERK levels are
shown with total Akt, total S6, and total ERK levels.
doi:10.1371/journal.pone.0037431.g007
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PLoS ONE | www.plosone.org 10 May 2012 | Volume 7 | Issue 5 | e37431KLE (group D) cells. All experiments were repeated 3 times, and
each value is shown as the mean of 3 experiments 6 S.D.
(PPT)
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